Epigenetic modulators in triple-negative breast cancer: epigenetic modifications and future treatment perspectives
Epigenomics · 03.08.2026 · 18 (8) · 993-1010
DOI: 10.1080/17501911.2026.2698002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epigenomics, online erschienen am 09.07.2026. Verfasst von Anita Choudhary und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Epigenesis, Genetic. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Anita Choudhary, University Grant Commission, Central University of Punjab.
Abstract (Originalsprache)
Triple Negative Breast Cancer (TNBC), an aggressive type of Breast Cancer (BC) characterized by the loss of expression of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal growth factor Receptor 2 (HER2) protein. TNBC is quite heterogenous in nature with limited available therapeutic options due to the lack of defined molecular targets. Epigenetic abnormalities have been implicated in the onset, progression, immune escape, and resistance to treatment in TNBC. Important epigenetic modulations, include DNA methylation, histone lactylation, histone modifications, and chromatin remodeling. Global hypomethylation contributes to genomic instability, while promoter hypermethylation inhibits tumor suppressor genes, by dysregulating their expression, thereby promoting uncontrolled proliferation, EMT, metastasis, and immune evasion in TNBC. Targeting epigenetic modulators, have the potential to develop novel therapeutic interventions have been developed and being explored. These epidrugs have proven to be effective in preclinical and clinical trials when used in combination with chemotherapy, immunotherapy, or targeted therapy, reducing drug resistance and aberrant proliferation. Despite of the advancements, challenges like target specificity, precise biomarkers and treatment related toxicity are the major hurdles. The review comprehensively summarized the important epigenetic alterations as well as novel treatment strategies with potential clinical applications in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India.
- Department of Microbiology, Central University of Punjab, Bathinda, India.
Förderung
- Anita Choudhary
- University Grant Commission
- Central University of Punjab
Zitieren
APA
Choudhary, A., Kumar, P., Kashyap, S., Patidar, V., Kumar, A., & Munshi, A. (2026). Epigenetic modulators in triple-negative breast cancer: epigenetic modifications and future treatment perspectives. Epigenomics, 18(8), 993-1010. https://doi.org/10.1080/17501911.2026.2698002
Vancouver
Choudhary A, Kumar P, Kashyap S, Patidar V, Kumar A, Munshi A. Epigenetic modulators in triple-negative breast cancer: epigenetic modifications and future treatment perspectives. Epigenomics. 2026;18(8):993-1010. doi:10.1080/17501911.2026.2698002
BibTeX
@article{Choudhary2026,
author = {Choudhary, Anita and Kumar, Pawan and Kashyap, Sohit and Patidar, Vishal and Kumar, Anil and Munshi, Anjana},
title = {Epigenetic modulators in triple-negative breast cancer: epigenetic modifications and future treatment perspectives},
journal = {Epigenomics},
year = {2026},
volume = {18},
number = {8},
pages = {993--1010},
doi = {10.1080/17501911.2026.2698002}
}
EUVIMED